Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 20/20 | 0.61 |
| ▸ | CCR3 | P51677 | 20/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 17/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4154387 | 0.82 | HRH1 (0.61) | HRH1CCR3KCNH2 | |
| SCHEMBL6242779 | 0.81 | HRH1 (0.72) | HRH1CCR3KCNH2 | |
| SCHEMBL5189852 | 0.81 | HRH1 (0.72) | HRH1CCR3KCNH2 | |
| SCHEMBL5194926 | 0.80 | HRH1 (0.62) | HRH1CCR3KCNH2 | |
| SCHEMBL5194599 | 0.79 | HRH1 (0.61) | HRH1CCR3KCNH2 | |
| SCHEMBL1929370 | 0.79 | HRH1 (0.60) | HRH1CCR3KCNH2 | |
| SCHEMBL5190415 | 0.79 | HRH1 (0.74) | HRH1CCR3KCNH2 | |
| SCHEMBL5191226 | 0.79 | HRH1 (0.74) | HRH1CCR3KCNH2 | |
| SCHEMBL5189696 | 0.78 | HRH1 (0.60) | HRH1CCR3KCNH2 | |
| SCHEMBL3941182 | 0.78 | KCNH2 (0.54) | HRH1CCR3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130023562-A1 | NOVEL PIPERIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2013-01-24 | — | — | US | disclosed |
| EP-1620400-B1 | piperidinylmethylpiperidine derivatives and their use as chemokine modulators | ASTRAZENECA AB (SE) | 2012-12-05 | — | — | EP | disclosed |
| US-8314127-B2 | Piperidine derivatives | ASTRAZENECA AB (SE) | 2012-11-20 | — | — | US | disclosed |
| EP-1912941-B1 | PIPERIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2012-11-14 | — | — | EP | disclosed |
| EP-2402316-A1 | Piperidine derivatives | AstraZeneca AB (Publ) (SE) | 2012-01-04 | — | — | EP | disclosed |
| US-20090118513-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2009-05-07 | — | — | US | disclosed |
| US-7495013-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2009-02-24 | — | — | US | disclosed |
| US-20080275084-A1 | Piperidines for the Treatment of Chemokine Mediated Diseases | ASTRAZENECA AB (SE) | 2008-11-06 | — | — | US | disclosed |
| US-20080262037-A1 | Piperidine Derivatives for the Treatment of Chemokine Mediated Disease | ASTRAZENECA AB (SE) | 2008-10-23 | — | — | US | disclosed |
| US-20080207688-A1 | Novel Piperidine Derivatives | ASTRAZENECA AB (SE) | 2008-08-28 | — | — | US | disclosed |
| US-20070032523-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2007-02-08 | — | — | US | disclosed |
| WO-2007011293-A1 | NOVEL PIPERIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-01-25 | — | — | WO | disclosed |
| EP-1735298-A1 | PIPERIDINE DERIVATES FOR THE TREATMENT OF CHEMOKINES MEDIARED DISEASE | AstraZeneca AB (SE) | 2006-12-27 | — | — | EP | disclosed |
| WO-2006126948-A1 | PIPERIDINES FOR THE TREATMENT OF CHEMOKINE MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2006-11-30 | — | — | WO | disclosed |
| US-20060040984-A1 | Novel piperidine derivatives for use in the treatment of chemokine medicated disease states | ASTRAZENECA AB (SE) | 2006-02-23 | — | — | US | disclosed |
| EP-1620400-A1 | CHEMICAL COMPOUNDS | AstraZeneca AB (SE) | 2006-02-01 | — | — | EP | disclosed |
| WO-2005097775-A1 | PIPERIDINE DERIVATES FOR THE TREATMENT OF CHEMOKINES MEDIARED DISEASE | ASTRAZENECA AB (SE) | 2005-10-20 | — | — | WO | disclosed |
| EP-1546130-A1 | NOVEL PIPERIDINE DERIVATIVES FOR USE IN THE TREATMENT OF CHEMOKINE MEDIATED DISEASE STATES | AstraZeneca AB (SE) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004087659-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2004-10-14 | — | — | WO | disclosed |
| WO-2004029041-A1 | NOVEL PIPERIDINE DERIVATIVES FOR USE IN THE TREATMENT OF CHEMOKINE MEDIATED DISEASE STATES | ASTRAZENECA AB (SE) | 2004-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207688-A1 | Novel Piperidine Derivatives | CCR3, CCR1, CCR4 | HRH1 276/4885CCR3 1/4885KCNH2 4090/4885 |
| US-20090118513-A1 | Chemical Compounds | CCR3, CCR1, CCR4 | HRH1 38/4885CCR3 1/4885KCNH2 4039/4885 |
| US-20070032523-A1 | Chemical compounds | CCR3, CCR1, CCR4 | HRH1 35/4885CCR3 1/4885KCNH2 3562/4885 |
| US-20080275084-A1 | Piperidines for the Treatment of Chemokine Mediated Diseases | CCR3, CCR1, CCR4 | HRH1 38/4885CCR3 1/4885KCNH2 2199/4885 |
| US-20130023562-A1 | NOVEL PIPERIDINE DERIVATIVES | CCR3, CCR1, CCR4 | HRH1 276/4885CCR3 1/4885KCNH2 4090/4885 |
| US-20060040984-A1 | Novel piperidine derivatives for use in the treatment of chemokine medicated disease states | CCR3, CCR1, CCL11 | HRH1 49/4885CCR3 1/4885KCNH2 3450/4885 |
| US-20080262037-A1 | Piperidine Derivatives for the Treatment of Chemokine Mediated Disease | CCR3, CCR1, CCR4 | HRH1 51/4885CCR3 1/4885KCNH2 3598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.